Prefer to view this content on our website? Click here.
The $200 Billion Weight-Loss Revolution Investors Can't Ignore
The weight-loss trade is not cooling off.
It's changing shape.
What started as a shortage-driven scramble around GLP-1 drugs is turning into something bigger: a full-blown ecosystem story built around access, distribution, branded drug economics, and the next wave of pipeline winners. That matters because this is no small niche. McKinsey says nearly 900 million adults globally live with obesity, and it sees GLP-1 sales reaching $100 billion by 2030. J.P. Morgan is even more aggressive, forecasting the broader incretin market could hit $200 billion by 2030.
That is why a single partnership announcement can send a stock flying.
When Hims & Hers said it had reached a new agreement with Novo Nordisk, the market did not treat it like a routine press release. It treated it like proof that the obesity trade is entering a new phase — one where branded products, cleaner distribution, and deeper penetration may matter even more than the old compounding boom.
Why Wall Street still can't get enough of GLP-1s
There's a simple reason this space keeps attracting capital.
Demand is still enormous.
Obesity is not a fad problem. It is a global, chronic, expensive condition. And once patients, providers, and payers decide a class of drugs actually works, the market tends to get a lot bigger than early forecasts suggest. That's what has been happening with GLP-1s. Prescriptions have been growing rapidly, the product pipeline is getting deeper, and drugmakers are now fighting over who controls the next layer of access.
That changes the investing math.
This is no longer just a "pick the drugmaker" story. It is also about who distributes these therapies, who owns the patient relationship, and who might develop the next generation of obesity treatments that are easier to take, better tolerated, or simply more scalable. In other words, the market is widening. And when a market widens, more stocks get pulled into the opportunity.
Sponsored by Med-X Inc.
Florida Is Testing New Alternative Pesticide
Med-X is moving toward a possible Nasdaq listing (ticker: MXRX) - and once that happens, the early window closes.
Before Wall Street prices it in, Med-X has already generated $6.4M in sales, placed Nature-Cide on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets.
Florida's mosquito control districts-America's most well-funded and influential-are independently testing Nature-Cide botanical pesticides, as Med-X pursues WHO pre-qualification for global public health adoption.
This is the gap before the bell.
Review the Med-X opportunity now - before Nasdaq plans unfold.
Disclosures: This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com
The access trade: Hims & Hers and Novo Nordisk
Company: Hims & Hers Health, Inc. (SYM: HIMS)
Telehealth platform expanding branded GLP-1 access.
Hims is where the market's attention went first.
And for good reason. The company said this week that it has entered into an agreement with Novo Nordisk that will bring Ozempic injections and Wegovy pills and injections to the Hims platform later this month. Hims also said it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, though it may still provide compounded access in limited cases where a provider determines it is clinically necessary. AP reported that Novo is dismissing its patent lawsuit as part of the agreement. Hims shares jumped more than 36% in Monday morning trading. Since then the stock has been trading around $27.46.
That's not just a headline pop.
It's the market recognizing that Hims may have moved from regulatory gray area into a much cleaner commercial lane. Instead of fighting over copycat semaglutide products, the company now gets to offer branded GLP-1s through a platform that already knows how to acquire and retain cash-pay patients. That could make Hims one of the most interesting "access layer" names in the whole obesity trade.
But this isn't necessarily a no-brainer.
Barron's reported that analysts at Citi, BofA, and Deutsche Bank all turned less negative after the deal, yet none came out with a buy rating. Their concern is straightforward: branded products may be cleaner legally, but they could also be less profitable than the compounded versions Hims had been offering. Analysts estimate Hims may need a big jump in subscriptions to replace that revenue. So yes, the overhang is smaller. But the execution bar is still high.
Company: Novo Nordisk A/S (SYM: NVO)
Global obesity-drug leader expanding distribution while defending branded economics.
The other side of this deal matters just as much.
Novo Nordisk is still the company that owns the blockbuster asset base here. Its agreement with Hims is not charity. It is a way to expand patient access, pull more demand back toward FDA-approved branded semaglutide, and reduce the pressure from knockoff versions that had started eating into the market. AP and the Financial Times both framed the agreement as the end of a feud and a meaningful commercial win for Novo. Novo's U.S.-listed shares have been trading around $38.74.
That gives investors two very different ways to play the same trend.
Hims is the higher-volatility platform trade.
Novo is the incumbent giant trying to keep more of the economics inside the branded tent.
American Alternative Assets
$3 trillion in fake money just hit the economy
Trump's "One Big Beautiful Bill" injected $3 trillion in borrowed money into everything.
Your stocks, your home value, your 401(k) - all artificially inflated.
When the spending stops, the bubble pops and your wealth could disappear.
The Big Beautiful Bubble Report shows you how to protect your retirement before the crash.
Download The Big Beautiful Bubble Report FREE
The pipeline trade: Viking and Structure still have room to surprise
Company: Viking Therapeutics, Inc. (SYM: VKTX)
Late-stage obesity developer with both injectable and oral VK2735 programs.
If you want torque, you move down the pipeline.
Viking still looks like one of the most credible next-wave obesity developers in the market. In its February update, the company said it had completed enrollment in VANQUISH-1, expects to complete enrollment in VANQUISH-2 this quarter, and plans to advance oral VK2735 into Phase 3 development in 3Q26 following end-of-Phase 2 FDA feedback. It also said a separate study evaluating monthly subcutaneous dosing plus daily and weekly oral dosing is fully enrolled, with results expected in Q3 2026. Viking shares are trading around $34.55.
That's a real calendar.
And real calendars matter in biotech because they give investors something concrete to reprice against. This is not just "promising science." It's a company moving an obesity asset through late-stage development while building optionality around dosing convenience and long-term maintenance. If the big obesity market really is headed into the $100 billion to $200 billion zone, names like Viking are exactly where investors go hunting for upside beyond the incumbents.
Company: Structure Therapeutics Inc. (SYM: GPCR)
Oral obesity-drug developer moving toward Phase 3 with outside validation.
Structure is a different kind of bet.
Investors first got excited here on earlier proof-of-concept data. But the story is more mature now. In December, the company reported positive results from its ACCESS II program, including placebo-adjusted weight loss of up to 15.3% at 36 weeks, and said it expects to initiate Phase 3 by mid-2026 after an FDA End-of-Phase 2 meeting. Its February business update reiterated Phase 3 initiation is expected in 2H 2026. Structure shares were trading around $58.25 on March 11.
Then came the extra validation.
In January, Fierce Biotech reported that Roche and Genentech agreed to pay $100 million upfront for a nonexclusive license to certain Structure patents related to CT-996, plus low-single-digit royalties on future net sales. That deal was not about charity either. It was about intellectual property, strategic positioning, and a recognition that Structure may own valuable ground in oral GLP-1 chemistry.
That;s what makes GPCR interesting.
It is not just another obesity hopeful.
It is a company with clinical momentum, a path toward Phase 3, and outside validation that its science and IP may matter more than the market thought.
So where does that leave you?
If you want the platform trade, Hims is the attention magnet.
If you want the established incumbent, Novo is the branded-economics play.
If you want pipeline upside, Viking and Structure are still the names with the sharper edge.
The demand is not going away.
And neither is the opportunity.
Trading Wire
Major Stock Movements Happening Now - Join Our Alert List
Quick question:
Do you want to catch stock moves early… or read about them afterward?
TradingWire sends real-time alerts when stocks begin making meaningful moves — straight to your inbox and phone.
Simple setup. Real signals. Fast delivery.
👉 Click here to sign up for email and SMS Alerts!
Alerts begin within minutes. No long-term commitment.
You can keep guessing — or get notified.
(By clicking the links above you agree to receive emails from Trading Wire. You can opt out at any time.)
Are there any other obesity-treatment focused healthcare stocks you've got your eye on right now? What other sectors of the market are you focusing on in 2026? Hit "reply" to this email and let us know your thoughts!
No comments:
Post a Comment